(NASDAQ: GH) Guardant Health's forecast annual revenue growth rate of 27.08% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.11%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.34%.
Guardant Health's revenue in 2026 is $1,080,215,000.On average, 28 Wall Street analysts forecast GH's revenue for 2026 to be $179,407,703,937, with the lowest GH revenue forecast at $169,330,109,333, and the highest GH revenue forecast at $183,783,501,594. On average, 28 Wall Street analysts forecast GH's revenue for 2027 to be $231,121,676,247, with the lowest GH revenue forecast at $211,496,886,755, and the highest GH revenue forecast at $265,597,657,787.
In 2028, GH is forecast to generate $296,758,641,102 in revenue, with the lowest revenue forecast at $262,547,859,420 and the highest revenue forecast at $387,854,792,325.